{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:53:28Z","timestamp":1750830808839},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.7759\/cureus.63675","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:39:57Z","timestamp":1719934797000},"source":"Crossref","is-referenced-by-count":1,"title":["Uncovering the Role of Direct Oral Anticoagulants in Stroke Prevention for Atrial Fibrillation: A Review of the Literature"],"prefix":"10.7759","author":[{"given":"Sudipta","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweatha","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abirami","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthana","family":"Veluswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-23.5.Cardio2","article-title":"Atrial fibrillation: a contemporary update","volume":"23","author":"Saleh K","year":"2023","unstructured":"Saleh K, Haldar S. Atrial fibrillation: a contemporary update. Clin Med (Lond). 2023, 23:437-41. 10.7861\/clinmed.2023-23.5.Cardio2","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.2311.812-a","article-title":"New methods of studying affections of the heart","volume":"1","author":"Mackenzie J","year":"1905","unstructured":"Mackenzie J. New methods of studying affections of the heart. Br Med J. 1905, 1:812-5. 10.1136\/bmj.1.2311.812-a","journal-title":"Br Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90013-2","article-title":"From rebellious palpitations to the discovery of auricular fibrillation: contributions of Mackenzie, Lewis and Einthoven","volume":"73","author":"Silverman ME","year":"1994","unstructured":"Silverman ME. From rebellious palpitations to the discovery of auricular fibrillation: contributions of Mackenzie, Lewis and Einthoven. Am J Cardiol. 1994, 73:384-9. 10.1016\/0002-9149(94)90013-2","journal-title":"Am J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh SS","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al.. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014, 129:837-47. 10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla S","year":"2013","unstructured":"Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013, 112:1142-7. 10.1016\/j.amjcard.2013.05.063","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.006350","article-title":"Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities)","volume":"11","author":"Mou L","year":"2018","unstructured":"Mou L, Norby FL, Chen LY, et al.. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018, 11:e006350. 10.1161\/CIRCEP.118.006350","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0027-9684(15)31212-8","article-title":"Racial differences in the prevalence of atrial fibrillation among males","volume":"100","author":"Borzecki AM","year":"2008","unstructured":"Borzecki AM, Bridgers DK, Liebschutz JM, Kader B, Kazis LE, Berlowitz DR. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc. 2008, 100:237-46. 10.1016\/s0027-9684(15)31212-8","journal-title":"J Natl Med Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.11.024","article-title":"Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis","volume":"25","author":"Rodriguez CJ","year":"2015","unstructured":"Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC Jr, Heckbert SR. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015, 25:71-6, 76.e1. 10.1016\/j.annepidem.2014.11.024","journal-title":"Ann Epidemiol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications","volume":"155","author":"Feinberg WM","year":"1995","unstructured":"Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995, 155:469-73.","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.108.795328","article-title":"Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation","volume":"2","author":"Nucifora G","year":"2009","unstructured":"Nucifora G, Schuijf JD, Tops LF, et al.. Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. Circ Cardiovasc Imaging. 2009, 2:100-6. 10.1161\/CIRCIMAGING.108.795328","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v15.i5.229","article-title":"Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship","volume":"15","author":"Batta A","year":"2023","unstructured":"Batta A, Hatwal J, Batta A, Verma S, Sharma YP. Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship. World J Cardiol. 2023, 15:229-43. 10.4330\/wjc.v15.i5.229","journal-title":"World J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14796678.2024.2354110","article-title":"Impact of initial high sensitivity C-reactive protein on outcomes in nonvalvular atrial fibrillation: an observational study","volume":"20","author":"Batta A","year":"2024","unstructured":"Batta A, Hatwal J, Panda P, Sharma Y, Wander GS, Mohan B. Impact of initial high sensitivity C-reactive protein on outcomes in nonvalvular atrial fibrillation: an observational study. Future Cardiology. 2024, 20:1-9. 10.1080\/14796678.2024.2354110","journal-title":"Future Cardiology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2022.0174","article-title":"Advances in basic and translational research in atrial fibrillation","volume":"378","author":"Hu D","year":"2023","unstructured":"Hu D, Barajas-Martinez H, Zhang ZH, et al.. Advances in basic and translational research in atrial fibrillation. Philos Trans R Soc Lond B Biol Sci. 2023, 378:20220174. 10.1098\/rstb.2022.0174","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048121","article-title":"Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling","volume":"143","author":"Yamaguchi N","year":"2021","unstructured":"Yamaguchi N, Xiao J, Narke D, et al.. Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling. Circulation. 2021, 143:805-20. 10.1161\/CIRCULATIONAHA.120.048121","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002906","article-title":"Atrial fibrillation: mechanism and clinical management","volume":"136","author":"Hu Z","year":"2023","unstructured":"Hu Z, Ding L, Yao Y. Atrial fibrillation: mechanism and clinical management. Chin Med J (Engl). 2023, 136:2668-76. 10.1097\/CM9.0000000000002906","journal-title":"Chin Med J (Engl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8102","article-title":"Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial","volume":"320","author":"Steinhubl SR","year":"2018","unstructured":"Steinhubl SR, Waalen J, Edwards AM, et al.. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018, 320:146-55. 10.1001\/jama.2018.8102","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.32.2.392","article-title":"Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project)","volume":"32","author":"Lamassa M","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G, et al.. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001, 32:392-8. 10.1161\/01.str.32.2.392","journal-title":"Stroke"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin HJ","year":"1996","unstructured":"Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996, 27:1760-4. 10.1161\/01.str.27.10.1760","journal-title":"Stroke"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/hm.hm_27_21","article-title":"Impact of atrial fibrillation on the severity, progress, and disability of the ischemic stroke patients","volume":"6","author":"Mavromoustakou K","year":"2022","unstructured":"Mavromoustakou K, Doundoulakis I, Soulaidopoulos S, et al.. Impact of atrial fibrillation on the severity, progress, and disability of the ischemic stroke patients. Heart and Mind . 2022, 6:26-31. 10.4103\/hm.hm_27_21","journal-title":"Heart and Mind"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip GY","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010, 137:263-72. 10.1378\/chest.09-1584","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.964023","article-title":"Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study","volume":"5","author":"Larsen TB","year":"2012","unstructured":"Larsen TB, Lip GY, Skj\u00f8th F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes. 2012, 5:335-42. 10.1161\/CIRCOUTCOMES.111.964023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.033","article-title":"Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database","volume":"66","author":"van den Ham HA","year":"2015","unstructured":"van den Ham HA, Klungel OH, Singer DE, Leufkens HG, van Staa TP. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol. 2015, 66:1851-9. 10.1016\/j.jacc.2015.08.033","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1597285","article-title":"Risk stratification models in atrial fibrillation","volume":"43","author":"Shahid F","year":"2017","unstructured":"Shahid F, Lip GY. Risk stratification models in atrial fibrillation. Semin Thromb Hemost. 2017, 43:505-13. 10.1055\/s-0036-1597285","journal-title":"Semin Thromb Hemost"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society","volume":"74","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al.. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019, 74:104-32. 10.1016\/j.jacc.2019.01.011","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof P","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al.. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016, 37:2893-962. 10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.194s","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers GW","year":"2001","unstructured":"Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001, 119:194S-206S. 10.1378\/chest.119.1_suppl.194s","journal-title":"Chest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7774","article-title":"Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature","volume":"175","author":"Seife C","year":"2015","unstructured":"Seife C. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature. JAMA Intern Med. 2015, 175:567-77. 10.1001\/jamainternmed.2014.7774","journal-title":"JAMA Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014, 383:955-62. 10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin\u00a0K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle T","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin\u00a0K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014, 12:320-8. 10.1111\/jth.12485","journal-title":"J Thromb Haemost"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13566","article-title":"Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis","volume":"15","author":"Kapoor A","year":"2017","unstructured":"Kapoor A, Ellis A, Shaffer N, et al.. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017, 15:284-94. 10.1111\/jth.13566","journal-title":"J Thromb Haemost"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen AT","year":"2016","unstructured":"Cohen AT, Harrington RA, Goldhaber SZ, et al.. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016, 375:534-44. 10.1056\/NEJMoa1601747","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip GY","year":"2018","unstructured":"Lip GY, Keshishian A, Li X, et al.. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018, 49:2933-44. 10.1161\/STROKEAHA.118.020232","journal-title":"Stroke"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao X","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016, 5:003725. 10.1161\/JAHA.116.003725","journal-title":"J Am Heart Assoc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","article-title":"Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents","volume":"27","author":"Rose DK","year":"2018","unstructured":"Rose DK, Bar B. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis. 2018, 27:2049-58. 10.1016\/j.jstrokecerebrovasdis.2018.04.004","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu J","year":"2018","unstructured":"Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018, 38:907-20. 10.1002\/phar.2158","journal-title":"Pharmacotherapy"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes GD","year":"2015","unstructured":"Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015, 128:1300-5.e2. 10.1016\/j.amjmed.2015.05.044","journal-title":"Am J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310672","article-title":"Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation","volume":"103","author":"Jackevicius CA","year":"2017","unstructured":"Jackevicius CA, Tsadok MA, Essebag V, et al.. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017, 103:1331-8. 10.1136\/heartjnl-2016-310672","journal-title":"Heart"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan N","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, et al.. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009, 37:74-81. 10.1124\/dmd.108.023143","journal-title":"Drug Metab Dispos"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost C","year":"2013","unstructured":"Frost C, Wang J, Nepal S, et al.. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013, 75:476-87. 10.1111\/j.1365-2125.2012.04369.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu181","article-title":"Edoxaban: a focused review of its clinical pharmacology","volume":"35","author":"Lip GY","year":"2014","unstructured":"Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014, 35:1844-55. 10.1093\/eurheartj\/ehu181","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech S","year":"2008","unstructured":"Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008, 36:386-99. 10.1124\/dmd.107.019083","journal-title":"Drug Metab Dispos"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (EXPLORE-Xa)","volume":"34","author":"Connolly SJ","year":"2013","unstructured":"Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (EXPLORE-Xa). Eur Heart J. 2013, 34:1498-505. 10.1093\/eurheartj\/eht039","journal-title":"Eur Heart J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02440-1","article-title":"Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences","volume":"40","author":"Cohen AT","year":"2023","unstructured":"Cohen AT, Sah J, Dhamane AD, et al.. Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences. Adv Ther. 2023, 40:1705-35. 10.1007\/s12325-023-02440-1","journal-title":"Adv Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025427","article-title":"Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban)","volume":"135","author":"Gibson CM","year":"2017","unstructured":"Gibson CM, Chi G, Halaby R, et al.. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. 2017, 135:648-55. 10.1161\/CIRCULATIONAHA.116.025427","journal-title":"Circulation"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"2013","author":"G\u00f3mez-Outes A","year":"2013","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez AI, Calvo-Rojas G, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013, 2013:640723. 10.1155\/2013\/640723","journal-title":"Thrombosis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2016.11.013","article-title":"Direct acting oral anticoagulant: bench to bedside","volume":"73","author":"Chadha DS","year":"2017","unstructured":"Chadha DS, Bharadwaj P. Direct acting oral anticoagulant: bench to bedside. Med J Armed Forces India. 2017, 73:274-81. 10.1016\/j.mjafi.2016.11.013","journal-title":"Med J Armed Forces India"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262670-uncovering-the-role-of-direct-oral-anticoagulants-in-stroke-prevention-for-atrial-fibrillation-a-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:40:01Z","timestamp":1719934801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262670-uncovering-the-role-of-direct-oral-anticoagulants-in-stroke-prevention-for-atrial-fibrillation-a-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.63675","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}